Lowest Price Guaranteed
Pages
607
Last Updated
July 2026
View Count
31076
The global antibody discovery market, valued at $2.0 billion in 2025, is projected to reach $2.2 billion in 2026 and $6.3 billion by 2035, representing a CAGR of 12.3% during the forecast period 2026 to 2035. This market includes the opportunity for antibody discovery service and technologies / platform providers across the full discovery workflow, from target identification and hit generation through lead selection, lead optimization, and preclinical validation.
To learn more about this report, request a free sample copy
The research study combines industry trends, market sizing, competitive landscape mapping, partnership and funding analysis, and market-impact assessment for biotechnology and pharmaceutical R&D stakeholders. It also models conservative, base and optimistic scenario to reflect uncertainty in R&D investment, regulatory timelines, and outsourcing trends.
| Key Report Attributes | Details | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 2.2 Billion | |
| Market Size 2035 | $ 6.3 Billion | |
| CAGR (Till 2035) | CAGR of 12.3% | |
Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins produced by B-lymphocytes. They recognize specific antigens, bind to them, and trigger immune mechanisms that neutralize or remove foreign substances. This biological specificity makes antibodies a dependable foundation for modern therapeutic discovery.
Scientists and researchers use therapeutic antibodies to address cancer, autoimmune disorders, asthma, rheumatoid arthritis, infectious diseases, and multiple rare conditions. Their ability to bind disease-relevant proteins with high specificity supports targeted treatment strategies and increasingly enables personalized medicine for biomarker-defined patient populations.
Advances in biotechnology and antibody engineering have expanded the available formats beyond conventional monoclonal antibodies to include bispecific antibodies, antibody drug conjugates, immunoconjugates, antibody fragments, and other engineered molecules. Each format offers a distinct mechanism for engaging biological targets.
Antibody programs have historically achieved higher approval rates than many new chemical entities. At the investigational new drug filing stage, antibody candidates have shown an approval probability of approximately 14%, compared with 7.6% for other new chemical entities (NCEs), which encourages pharmaceutical companies to sustain antibody-focused R&D investment.
The commercial and clinical potential of therapeutic antibodies continues to drive discovery investment. In 2024, the USFDA approved 10 monoclonal antibodies, representing close to 20% of new drug approvals and reinforcing the importance of efficient target identification, validation, and candidate optimization.
The discovery workflow begins with target identification and validation, followed by hit generation through hybridoma technology, phage display, transgenic animal platforms, yeast display, or single-cell-based techniques. Leads are then selected using specificity, developability, and manufacturability criteria before optimizing affinity, stability, and safety for preclinical testing.
Many biotechnology companies outsource discovery work because they lack the specialized talent, screening infrastructure, animal models, libraries, and computational resources required to manage every stage internally. Contract research organizations and platform suppliers provide flexible access to validated workflows while allowing clients to control development timelines and intellectual property strategy.
Artificial intelligence, machine learning, high-throughput screening, automation, and computational modelling now help researchers predict antigen-antibody interactions, prioritize candidates, and reduce experimental cycles. Single-cell sequencing and single-cell analysis further improve clone selection, while advanced platform providers combine these tools to shorten early discovery timelines.
Roots Analysis defines the antibody discovery market as the combined opportunity across antibody discovery services and antibody discovery technologies and platforms, segmented by discovery step, discovery method, nature of antibody, therapeutic area, type of antibody, end-user, and geography, as detailed in the segmentation table above.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders across the antibody discovery value chain. These discussions informed the assessment of discovery workflows, outsourcing behaviour, technology adoption, partnership activity, funding, regulatory considerations, and commercial opportunities. These have been listed below:
Emphasizing the recent advancements in antibody discovery, Carl Hansen (Founder and Chief Executive Officer, AbCellera), stated, "Yeah, I think antibody therapies have a tremendous future. Starting with some very important technology developments and discoveries in the late '90s, early 2000s, we proved that this was a viable therapeutic modality, and this sector has now grown tremendously. So, I'd say over the last 10, 15 years, it has been one of, if not the most, most important and one of the fastest growing. So, it's gone from zero to maybe $180 billion in total market and 100 approved therapies"
The market report presents an in-depth analysis of the various firms / organizations that are engaged in providing services or platforms for the discovery of antibodies, across different segments, as defined in the table below.
One of the key objectives of this market report was to estimate the current antibody discovery services and technologies / platforms market size, opportunity and future growth potential over the forecast period. Based on multiple relevant parameters, adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.
| Key Segmentations | Details | |
| Antibody Discovery Step | Hit Generation, Lead Selection, Lead Optimization | |
| Antibody Discovery Method | Hybridoma-based, Phage Display Library-based, Transgenic Animal-based, Yeast Display-based, Single Cell-based, Other Methods | |
| Nature of Antibody | Human, Humanized, Chimeric, Murine | |
| Therapeutic Area | Oncological, Immunological, Infectious, Cardiovascular, Neurological, Other Disorders | |
| Type of Antibody | Monoclonal, Bispecific, Antibody Drug Conjugates, Immunoconjugates, Other Antibodies | |
| End-user | In-house Players, Contract Research Organizations | |
| Geographical Regions | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Switzerland and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia and Singapore), Middle East and North Africa (Egypt, Israel, Saudi Arabia, and Rest of Middle East and North Africa), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America) | |
The overall market has been segregated across antibody discovery services and platforms. Detailed insights related to these have been presented in the sections below.
Lead optimization currently accounts for 61% of the overall market because it ensures high quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success. This process is integral to minimizing off-target effects and optimizing pharmacokinetics, which is crucial for the development of safe and effective therapeutics ahead of preclinical testing.
Hybridoma-based methods currently account for 35% of the market because many laboratories value their established workflows, biological relevance, and relatively low technical complexity.
Hybridoma technology has supported the development of therapeutic monoclonal antibodies for cancer, autoimmune disorders, and infectious diseases. Immunization of host animals underpins hit generation, while single-cell sequencing and analysis increasingly accelerates clone identification and improve antibody-diversity assessment.
Since Kohler and Milstein introduced hybridoma technology in 1975, researchers have used the method to develop multiple approved antibodies, including adalimumab, Opdivo, and Tecentriq. Modern laboratories now combine established hybridoma workflows with automation and high-throughput screening to improve productivity.
Human antibodies currently account for 53% of the market because they generally reduce immunogenicity risk and provide a longer serum half-life than murine or chimeric formats.
Developers increasingly use transgenic animal platforms, phage display, and single-cell approaches to discover fully human antibodies. More than 15 fully human monoclonal antibodies received approvals across different geographies in 2024, supporting continued demand for human-antibody discovery capabilities.
Oncological disorders account for 48% of the overall market. Rising cancer incidence, extensive target biology, and sustained pharmaceutical investment continue to drive discovery activity across solid tumors and hematological malignancies.
Antibody-based therapies have delivered clinically meaningful results in oncology, while developers are expanding targeted discovery programs in cardiovascular disease. Growing demand for precise mechanisms, improved selectivity, and biomarker-led development is expected to support faster growth in cardiovascular applications.
Monoclonal antibodies account for 60% of the antibody discovery services market because they offer high specificity, reproducibility, and broad therapeutic applicability. Their established regulatory history and continued use in cancer, autoimmune disorders, and infectious diseases support sustained demand for monoclonal antibody discovery services.
Within the technologies and platforms segment, monoclonal-antibody discovery capabilities hold a 51% share. The USFDA approved 10 monoclonal antibodies in 2024, reinforcing demand for platforms that can generate differentiated candidates with strong binding, developability, and manufacturability profiles.
Bispecific-antibody technologies and platforms are projected to grow at a CAGR of 9.51% through 2035. Their ability to bind two targets, improve selectivity, and redirect immune cells toward disease-relevant pathways is encouraging biotechnology companies to license specialized discovery platforms.
In-house pharmaceutical and biotechnology teams account for 98% of the technologies and platforms market. These organizations maintain dedicated scientific teams, proprietary datasets, internal screening capabilities, and direct control over intellectual property, which helps them integrate discovery decisions with development and portfolio strategy.
Academic and research laboratories represent a smaller revenue share but play an important role in early target identification and validation. Contract research organizations complement these laboratories by providing scalable hit-generation, lead-selection, engineering, and optimization capacity to clients that cannot justify a fully internal discovery function.
North America is likely to capture the majority (50%) share of the market, owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. Asia-Pacific is poised for a healthy growth rate (with a CAGR of 13.3%) during the forecast period.
Similarly, the technologies and platforms market is segmented across various geographies, including North America (US and Canada), Europe (UK, Switzerland, Germany, France, and Rest of Europe) and Asia-Pacific (China, Japan, South Korea and Singapore). North America is projected to capture majority of the overall market share, driven by maximum number of technology licensing and integration deals inked by technology and platform providers headquartered in this region. The market in Asia-Pacific is anticipated to rise at a faster pace (CAGR of 9.30%) as a result of the ongoing efforts of companies for expanding their antibody discovery processes in this region for long-term growth and success.
The report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the players involved in this domain. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biotechnology and pharmaceutical industry.
Close to 125 service providers operate in the market. Small companies account for 43% of the landscape, reflecting strong startup formation and sustained demand for specialized discovery expertise. Examples of post-2015 startups include Ab Studio, AlivaMab Biologics, Alpha Lifetech, Atlantis Biosciences, Jotbody, and Specifica.
Close to 265 technologies and platforms are provided by industry players active in this domain. Of these, majority (59%) of the technologies and platforms employ library-based method for the discovery of antibodies, followed by technologies using single cell method (33%). Notable examples of technologies that employ library-based method, provided by mid-sized companies, include Dynamic Precision Library Platform and NEObody (provided by Adagene), Adimab technology (provided by Adimab), SHM (provided by AnaptysBio) and n-CoDeR antibody library (provided by BioInvent).
Approximately 68% of technologies and platforms support monoclonal-antibody discovery. Representative offerings include AbStudio's Imbalanced Bispecific Antibody Platform and Serial Internalizing Antibody Platform, Abcam's RabMab technology, and AbCellera's discovery platform.
Biotechnology companies increasingly combine AI, machine learning, high-throughput screening, automation, and single-cell analysis to predict antigen-antibody interactions and prioritize candidates. These tools reduce experimental cycles, improve discovery precision, and strengthen platform differentiation.
Rising demand for targeted therapies encourages developers to discover antibodies for narrower, biomarker-defined populations. Humanization, bispecific design, and advanced engineering improve selectivity and support personalized-medicine strategies across oncology, immunology, cardiovascular disease, and rare disorders.
Pharmaceutical R&D spending and investor capital continue to expand discovery pipelines and technology portfolios. Market participants have raised more than USD 36 billion since 2021, while Thermo Fisher Scientific recorded the largest reported funding amount through debt financing.
Biotechnology startups and mid-sized developers increasingly outsource target validation, hit generation, engineering, and lead optimization to CROs and specialist providers. Outsourcing gives clients flexible access to expertise, libraries, animal models, and screening capacity without major capital investment.
Continued USFDA and EMA activity reinforces confidence in therapeutic antibodies while increasing demand for rigorous preclinical validation, developability assessment, compliance, and safety data. Discovery providers that generate traceable, regulatory-ready evidence can become more valuable development partners.
Technology providers, pharmaceutical companies, biotechnology startups, academic institutions, and other stakeholders form alliances for product licensing, platform access, research and development, and technology utilization. Since 2021, technology providers have entered more than 270 strategic partnerships; R&D agreements represented 30% of 2024 activity.
Recent licensing agreements include Harbour BioMed with Windward Bio, Hummingbird Biosciences with Immunome, Antibody Solutions with Leveragen, and Harbour BioMed with Kodiak Sciences. Merus also partnered with Biohaven to co-develop three bispecific antibody drug conjugates using complementary antibody and conjugation platforms.
North America currently holds 60% of the technologies and platforms market. The region combines established biotechnology clusters, experienced researchers, strong venture investment, and active licensing markets, which encourage technology providers to launch and commercialize antibody discovery platforms.
Asia-Pacific is projected to grow at a CAGR of 9.30% through 2035 as regional companies expand platform capabilities and global collaborations. North American AI-enabled providers include Absci, Alloy Therapeutics, BigHat Biosciences, Creative Biolabs, GV20 Therapeutics, HiFiBio Therapeutics, ImmunoPrecise Antibodies, and OmniAb.
The report profiles Ablexis, Abwiz Bio, Abzena, Aragen Life Sciences, BIOTEM, ChemPartner, Creative Biolabs, DetaiBio, FairJourney Biologics, Fusion Antibodies, Genmab, Harbour BioMed, Immunome, ImmunoPrecise Antibodies, Integral Molecular, Isogenica, ProteoGenix, Syd Labs, Viva Biotech, and WuXi Biologics. The searchable Excel database covers close to 300 companies. Thermo Fisher Scientific, Merck, Evotec, and Abcam also appear in the wider ecosystem analysis through funding, technology, or partnership activity.
After a lead antibody clears preclinical validation, developers transfer the program into cell-line development, process development, and manufacturing. Companies without in-house biologics capacity often work with a CDMO. Providers such as WuXi Biologics span adjacent discovery and manufacturing activities, which can simplify technology transfer and manufacturing scale-up.
Academic laboratories frequently identify novel targets and validate disease biology before licensing or spinning out a program. CROs give biotechnology clients access to hit generation, lead selection, engineering, and optimization without requiring them to build an internal discovery function or commit substantial capital.
Companies should define ownership of antibody sequences, platform-generated intellectual property, discovery methods, data, and manufacturing-related know-how before starting a partnership. They should also evaluate freedom to operate, patent strategy, compliance history, and safety-data practices because these factors can affect licensing value and downstream development.
Alongside the core market report, purchasers receive complimentary Excel data packs covering the antibody discovery service providers' market landscape, antibody discovery technologies and platforms market landscape, company competitiveness analysis, technology competitiveness analysis, partnerships and collaborations analysis, funding and investment analysis, service providers' market sizing and opportunity analysis, and platforms and technologies market sizing and opportunity analysis. A complimentary PowerPoint presentation summarizing the full report is also included, and 15% free customization scope is available on request.
Author(s): This report was co-authored by Dhriti Gulati and Muskan Arora, both part of the Roots Analysis's healthcare and pharmaceutical research practice, with a focus on biologics discovery, development, manufacturing, competitive intelligence, and market forecasting.
Roots Analysis is an independent market research and consulting firm. This report draws on publicly available information, primary interviews, and proprietary analysis. Roots Analysis is not affiliated with, endorsed by, or a representative of the USFDA, the European Medicines Agency, or any of the companies, technologies, or individuals named in this report. Figures are derived from primary interviews with industry stakeholders combined with secondary research, and are not directly comparable to market-sizing studies published by other research firms that draw the antibody discovery segment boundary differently, for example by including or excluding manufacturing and CDMO-adjacent revenue. All company and product names are used for identification purposes only and remain the property of their respective owners.
Clients evaluating this report alongside competing market studies should weigh how the publisher defines the segment boundary, since antibody discovery market sizing is not standardized across research firms and some studies fold in adjacent manufacturing or CDMO revenue that this report treats separately. This report, by Roots Analysis is updated on a sixth-edition cadence, includes discovery-step and discovery-method segmentation not always present in competing studies, and now carries the explicit scope, methodology, and non-affiliation disclosure set out above.